DebraJeanKelshMD

Psychiatry • Kansas City, KS

Physician

Join to view full profile

Dr. Kelsh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kelsh's full profile

Already have an account?

Office
3901 Rainbow Blvd
Kansas City, KS 66160
Phone+1 913-588-1304

Fax+1 913-588-1310

Education & Training

University of Kansas School of MedicineResidency, Psychiatry, 1992 - 1996
University of Kansas School of MedicineResidency, Internal Medicine, 1991 - 1991
University of Kansas School of MedicineClass of 1991

Certifications & Licensure

KS State Medical License 1995 - 2025
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) Start of enrollment: 2011 Jan 17
Completed
Phase 3
Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers Start of enrollment: 2016 Jul 01
Completed
Phase 1
Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers Start of enrollment: 2017 Jun 01
Completed
Phase 1
Comparison of Naloxone Pharmacokinetics Start of enrollment: 2018 Jan 03
Completed
Phase 1
Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam Start of enrollment: 2017 Dec 04
Completed
Phase 1
Evaluation of Abuse Liability of Very Low Nicotine (VLN) Mentholated Cigarettes Start of enrollment: 2018 May 01
Completed
Phase 1
Evaluation of the Abuse Liability of Very Low Nicotine (VLN) Cigarettes Start of enrollment: 2018 Apr 13
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

51 citations
Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
Sharon L. Walsh, Sandra D. Comer, Michelle R. Lofwall, Bradley Vince, Naama Levy-Cooperman
JAMA Psychiatry. 2017-09-01
22 citations
Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
Mike Ufer, Debra Kelsh, Kerri A. Schoedel, Jasper Dingemanse
Sleep. 2021-09-04
9 citations
Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial
Sanjeev Pathak, Bradley Vince, Debra Kelsh, Megan J. Shram, Beatrice Setnik
Journal of Clinical Pharmacology. 2019-02-01